Editorials: Sulphasalazine in rheumatoid arthritis: an old drug revived

Neumann, V. C.; Grindulis, K. A.
March 1984
Journal of the Royal Society of Medicine;Mar1984, Vol. 77 Issue 3, p169
Academic Journal
The article discusses the benefits of sulphasalazine in treating rheumatoid arthritis. Sulphasalazine is an old drug which is a compound of sulphapyridine and 5-aminosalicylic acid linked by an azo bond. The benefits of salicylates in rheumatoid arthritis have an excellent effect on the sensations of pain, but have little effect especially in chronic cases.


Related Articles

  • Disease-modifying drugs in rheumatoid arthritis. Warburton, Louise // Update;Jun2007, Vol. 74 Issue 6, p30 

    The article presents information on the therapeutic use of disease-modifying drugs (DMARDs) in rheumatoid arthritis (RA). It is reported that early diagnosis of RA enables early therapeutic intervention with DMARDs and a much better prognosis for the patient. Recently published guidelines of the...

  • Non-drug care for RA—is the era of evidence-based practice approaching? Vlieland, T. P. M. Vliet // Rheumatology;Sep2007, Vol. 46 Issue 9, p1397 

    Non-pharmacological treatment modalities are often recommended, prescribed and used in addition to drug treatment in patients with rheumatoid arthritis (RA). This article provides a review of the literature on their effectiveness.

  • How does the Short Form 36 Health Questionnaire (SF-36) in Rheumatoid Arthritis (RA) Relate to RA Outcome Measures and SF-36 Population Values? A Cross-Sectional Study. Birrell, F. N.; Hassell, A. B.; Jones, P. W.; Dawes, P. T. // Clinical Rheumatology;May2000, Vol. 19 Issue 3, p195 

    : The aim of the study was to show that the SF-36 is a practical tool for use on outpatients with RA, to examine the relationship between the SF-36 and indices of outcome in RA, and to compare the results with population norms and other disease states. Eighty-six consecutive RA patients...

  • Biomarker und personalisierte Medizin. Scherer, H.U.; Burmester, G.-R.; Häupl, T. // Zeitschrift für Rheumatologie;Feb2013, Vol. 72 Issue 1, p20 

    Biomarkers form the basis for patient stratification and the development of individualized treatment strategies. As the understanding of the pathophysiological processes underlying rheumatic diseases increases, novel biomarkers will become available and established markers can be used more...

  • When It Comes to TREATMENT, Early is Best. Mann, Denise; Siegfried, Donna Rae // Arthritis Today;May2005, Vol. 19 Issue 3, p38 

    Focuses on the benefits of early treatment for rheumatoid arthritis (RA). Drugs used for the treatment of RA; Risk of a patient for persistent disease; Achievement by people with early RA of clinical remission.

  • Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Péntek, Márta; Poór, Gyula; Wiland, Piotr; Olejárová, Martina; Brzosko, Marek; Codreanu, Catalin; Brodszky, Nóra; Gulácsi, László // European Journal of Health Economics;May2014 Supplement, Vol. 15, p35 

    Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug...

  • Formulation and evaluation of fast dispersible tablets of aceclofenac. Shivprasad, Majumdar; Dhiraj, Nikam // Journal of Pharmacy Research;Aug2009, Vol. 2 Issue 8, p1296 

    Aceclofenac a non-steroidal anti-inflammatory drug, used in posttraumatic pain and rheumatoid arthritis. Aceclofenac fast-dispersible tablet have been prepared by direct compression method using microcrystalline cellulose as a direct compressible vehicle. Croscarmellose sodium and polyplasdone...

  • Rheumatoid arthritis: chronic, painful, but treatable. Sjoblom, Beth // South County Journal;4/4/2012, Vol. 47 Issue 14, pB2 

    The article discusses the treatment of rheumatoid arthritis, an autoimmune disease that affects 1.3 million of the population in the U.S.

  • Clinical Entity of Amavata. Joshi, Vimal; Mehta, Charmi; Sharma, Manisha; Dave, Alankruta // Indian Journal of Ancient Medicine & Yoga;Jan-Mar2012, Vol. 5 Issue 1, p37 

    Amavata is described in detail as a distinct clinical entity by Acharya Madhavakara in Madhavanidana. It is a disease of Madhyama roga marga affecting Asthisandhi in which the pain is similar to that of scorpion bite. Since many years, most of scholars have correlated Amavata to rheumatoid...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics